Roche’s subcutaneous lunsumio receives CHMP backing for R/R follicular lymphoma

Real-world data shows strong symptom relief and patient satisfaction with Teva’s Austedo XR

Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer

Importantly, the combination of giredestrant and everolimus was well tolerated

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent

Metropolis Healthcare acquires Ambika Pathology Laboratory

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada

Fermenta to sell environmental solutions business to its subsidiary

The entity will undertake the installation, operation, and maintenance of sewage treatment plants

FDA approves Merck's Keytruda injection for cancer therapy

Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025

The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States